Vimarsana
Biggest News Aggregation in the World

Page 10 - Vitro Diagnostics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Vitro Diagnostics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Vitro Diagnostics Today - Breaking & Trending Today

Pharmaceutical Contract Manufacturing Market to grow by USD 58 billion from 2022 to 2027, North America to account for 41% of market growth - Vimarsana News

Pharmaceutical Contract Manufacturing Market to grow by USD 58 billion from 2022 to 2027, North America to account for 41% of market growth

/PRNewswire/ -- The pharmaceutical contract manufacturing market is expected to grow by USD 58 billion from 2022 to 2027. In addition, the momentum of the...

Financial Review: Surmodics (NASDAQ:SRDX) and Venus Concept (NASDAQ:VERO) - Vimarsana News

Financial Review: Surmodics (NASDAQ:SRDX) and Venus Concept (NASDAQ:VERO)

Venus Concept (NASDAQ:VERO – Get Free Report) and Surmodics (NASDAQ:SRDX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends. Earnings and Valuation This table compares Venus Concept […]

WHO Announces Second Week of Quality Training: Registrations Now Open for the In Vitro Diagnostics Training - Vimarsana News

WHO Announces Second Week of Quality Training: Registrations Now Open for the In Vitro Diagnostics Training

Join us for the WHO's Week of Quality for IVDs training program. Register your interest to participate in this valuable training program. IVD manufacturers and regulatory authorities (Ministry of Health, National Regulatory Authorities) in all WHO regions are welcome to attend.

Source: who.int
Surmodics' (SRDX) "Neutral" Rating Reiterated at Sidoti - Vimarsana News

Surmodics' (SRDX) "Neutral" Rating Reiterated at Sidoti

Sidoti reiterated their neutral rating on shares of Surmodics (NASDAQ:SRDX – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. The brokerage currently has a $43.00 target price on the stock. SRDX has been the topic of a number of other reports. Needham & Company LLC reaffirmed a hold rating on […]

Lake Street Capital Reaffirms Hold Rating for Surmodics (NASDAQ:SRDX) - Vimarsana News

Lake Street Capital Reaffirms Hold Rating for Surmodics (NASDAQ:SRDX)

Lake Street Capital reissued their hold rating on shares of Surmodics (NASDAQ:SRDX – Free Report) in a research report report published on Wednesday, Marketbeat reports. Lake Street Capital currently has a $43.00 target price on the stock. SRDX has been the subject of a number of other research reports. StockNews.com cut Surmodics from a strong-buy […]

Source: wkrb13.com